“Bimekizumab Maintenance of Response through Three Years in Patients With Moderate to Severe Plaque Psoriasis Who Responded at Week 16: Results from the BE BRIGHT Open-Label Extension Trial”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): s65. https://doi.org/10.25251/skin.6.supp.65.